On June 12, 2020 Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics for cancer, reported that the company will present new data in scientific posters to be presented at the 2020 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting II, which will be held online, June 22-24, 2020 (Press release, Personalis, JUN 22, 2020, View Source [SID1234561338]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
These abstract showcases data from ImmunoID NeXT, the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample. The ImmunoID NeXT Platform can be used to investigate the key tumor- and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one and maximizing the biological information that can be generated from a precious tumor specimen.
Following are details and links to the scientific posters that will be presented at the online meeting.
Abstract Number, Session Category and Session Title
Title & Presenter
Date
Location
2085 / 2
Bioinformatics and Systems Biology
Machine Learning
Precision neoantigen discovery using a pan-allelic machine learning model for enabling the development of composite biomarkers and personalized immunotherapy
Presenter: Datta Mellacheruvu
June 22, 2020
Online
1989 / 26
Clinical Research
Circulating Markers 2
Enhanced whole exome profiling of tumor circulating cell-free DNA enables sensitive assessment of tumor mutations
Presenters: Mengyao Tan and Simo V. Zhang
June 22, 2020
Online
1334 / 29
Molecular and Cellular Biology/Genetics
Genomic Profiling of Tumors 2
A diagnostic platform for precision cancer therapy enabling composite biomarkers by combining tumor and immune features from an enhanced exome and transcriptome
Presenter: Robert Power
June 22, 2020
Online
2512 / 28
Molecular and Cellular Biology/Genetics
Genomic Profiling of Tumors 3
Pan-cancer characterization of the tumor and immune microenvironment facilitates identification of cancer-specific biological signatures
Presenter: Sean M. Boyle
June 22, 2020
Online
4430 / 25
Bioinformatics and Systems Biology
Tumor Heterogeneity and Microenvironment: Next-Generation Sequencing, Single Cell, and Imaging
Quantification of tumor-infiltrating immune cell populations with an augmented transcriptome
Presenter: Eric Levy
June 22, 2020
Online
4278 / 2
Clinical Research
Predictive Biomarkers for Treatment Efficacy 3
A composite neoantigen score is more strongly associated with therapeutic response than tumor mutational burden in a cohort of late-stage anti-PD-1-treated melanoma patients
Presenter: Charles Abbott
June 22, 2020
Online
6678 / 24
Immunology
Immune Response to Therapies 2
Sensitive HLA loss of heterozygosity detection reveals allele-specific neoantigen expansion as resistance mechanism to anti-PD-1 therapy
Presenter: Rachel Marty Pyke
June 22, 2020
Online
852 / 2
Bioinformatics and Systems Biology
Machine Learning and Artificial Intelligence for Omics, Imaging, and Diagnostics
Improved tumor-only somatic variant calling using a gradient boosted machine learning algorithm
Presenter: Nick Phillips